BLOCKADE OF BCL-2 PROTEINS EFFICIENTLY INDUCES APOPTOSIS IN PROGENITOR CELLS OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS

被引：1
|
作者：
Jilg, S. [1 ]
Reidel, V. [1 ]
Mueller-Thomas, C. [1 ]
Koenig, J. [1 ]
Schauwecker, J. [2 ]
Burgkart, R. [2 ]
Hoeckendorf, U. [1 ]
Huberle, C. [1 ]
Gorka, O. [3 ]
Ruland, J. [3 ]
Kolb, H. [1 ]
Peschel, C. [1 ]
Oostendorp, R. [1 ]
Goetze, K. [1 ]
Jost, P. [1 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 3, D-80290 Munich, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Dept Orthoped, D-80290 Munich, Germany
[3] Tech Univ Munich, Klinikum Rechts Isar, Dept Clin Chem, D-80290 Munich, Germany
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30028-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
27
引用
收藏
页码：S12 / S12
页数：1
相关论文
共 50 条
  • [31] BCL-2 system analysis identifies high-risk colorectal cancer patients
    Lindner, Andreas U.
    Salvucci, Manuela
    Morgan, Clare
    Monsefi, Naser
    Resler, Alexa J.
    Cremona, Mattia
    Curry, Sarah
    Toomey, Sinead
    O'Byrne, Robert
    Bacon, Orna
    Stuhler, Michael
    Flanagan, Lorna
    Wilson, Richard
    Johnston, Patrick G.
    Salto-Tellez, Manuel
    Camilleri-Broet, Sophie
    McNamara, Deborah A.
    Kay, Elaine W.
    Hennessy, Bryan T.
    Laurent-Puig, Pierre
    Van Schaeybroeck, Sandra
    Prehn, Jochen H. M.
    GUT, 2017, 66 (12) : 2141 - 2148
  • [32] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    Fenaux, P.
    Mufti, G. J.
    Hellstrom-Lindberg, E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 395 - 395
  • [33] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    不详
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (02) : 120 - 120
  • [34] Combined chemotherapy for patients with high risk myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS.
    Shi, J
    Shao, ZH
    Liu, H
    Chen, GB
    Zhang, YZ
    Bai, J
    He, GS
    Fu, R
    Zhao, MF
    Cao, YR
    Wu, YH
    Jing, LP
    Hao, YS
    Yang, TY
    BLOOD, 2003, 102 (11) : 13B - 13B
  • [35] Upregulation of S100A6 and its relation with CD34+ cells apoptosis in high-risk myelodysplastic syndromes patients
    Zhai, Yan
    Meng, Fanqiao
    Li, Jiaojiao
    Ma, Junlan
    Shen, Li
    Zhang, Wei
    HELIYON, 2023, 9 (08)
  • [36] Assessment Of EZH2 Expression In CD34+Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS)
    Wei, Yue
    Zheng, Hong
    Yang, Hui
    Chen, Rui
    Wang, Hui
    Wane, Xia
    Garcia-Manero, Guillermo
    BLOOD, 2013, 122 (21)
  • [37] Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
    Grovdal, Michael
    Karimi, Mohsen
    Khan, Rasheed
    Aggerholm, Anni
    Antunovic, Petar
    Astermark, Jan
    Bernell, Per
    Engstrom, Lena-Maria
    Kjeldsen, Lars
    Linder, Olle
    Nilsson, Lars
    Olsson, Anna
    Holm, Mette S.
    Tangen, Jon M.
    Wallvik, Jonas
    Oberg, Gunnar
    Hokland, Peter
    Jacobsen, Sten E.
    Porwit, Anna
    Hellstrom-Lindberg, Eva
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (03) : 293 - 302
  • [38] The Different Immunoregulatory Functions of Mesenchymal Stem Cells in Patients with Low-Risk or High-Risk Myelodysplastic Syndromes
    Zhao, Zhigang
    Wang, Zhenling
    Li, Qiubai
    Li, Weiming
    You, Yong
    Zou, Ping
    PLOS ONE, 2012, 7 (09):
  • [39] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
    Santini, V.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    List, A. F.
    Silverman, L. R.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Arctigenin induces Apoptosis in Melanoma Cells by Reducing the Expression of BCL-2 and VEGF
    Gao, Yang
    Wang, He-peng
    Wang, Hai-fei
    Ma, Shi-meng
    Du, Zi-wei
    Liu, Jia
    TRANSPLANTATION PROCEEDINGS, 2024, 56 (02) : 448 - 452
12345